^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

INCB86550

i
Other names: INCB86550, INCB-86550, INCB-086550, INCB 086550, INCB086550
Company:
Incyte
Drug class:
PD-L1 inhibitor
Related drugs:
7ms
Study of INCB086550 in Select Solid Tumors (clinicaltrials.gov)
P2, N=16, Terminated, Incyte Corporation | Trial completion date: Aug 2024 --> Mar 2024 | Active, not recruiting --> Terminated; Strategic business decision to terminate the study effective immediately. This is due to a company decision to prioritize another oral PD-L1 inhibitor with a more favorable profile.
Trial completion date • Trial termination • Checkpoint inhibition
|
INCB86550
12ms
Trial completion • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
INCB86550
over1year
Trial completion date • Metastases
|
MSI (Microsatellite instability)
|
PD-L1 expression • MSI-H/dMMR
|
INCB86550
over1year
Study of INCB086550 in Select Solid Tumors (clinicaltrials.gov)
P2, N=16, Active, not recruiting, Incyte Corporation | N=150 --> 16 | Trial completion date: May 2023 --> Aug 2024 | Trial primary completion date: May 2023 --> Mar 2024
Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition
|
INCB86550
over1year
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=138, Active, not recruiting, Incyte Corporation | Trial completion date: Feb 2023 --> Sep 2023 | Trial primary completion date: Feb 2023 --> Sep 2023
Trial completion date • Trial primary completion date • Metastases
|
MSI (Microsatellite instability)
|
PD-L1 expression • MSI-H/dMMR
|
INCB86550
almost3years
Clinical • Enrollment closed
|
MSI (Microsatellite instability)
|
PD-L1 expression • MSI-H/dMMR
|
INCB86550
3years
Clinical • Enrollment change
|
MSI (Microsatellite instability)
|
PD-L1 expression • MSI-H/dMMR
|
INCB86550
over3years
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=372, Recruiting, Incyte Corporation | N=230 --> 372 | Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Sep 2022 --> Dec 2022
Clinical • Enrollment change • Trial completion date • Trial primary completion date
|
MSI (Microsatellite instability)
|
PD-L1 expression • MSI-H/dMMR
|
INCB86550
over3years
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=230, Recruiting, Incyte Corporation | N=128 --> 230 | Trial completion date: Aug 2021 --> Sep 2022 | Trial primary completion date: Jun 2021 --> Sep 2022
Clinical • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker
|
MSI (Microsatellite instability)
|
PD-L1 expression • MSI-H/dMMR
|
INCB86550